Cargando…
Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
Various mechanisms of treatment resistance have been reported for glioblastoma (GBM) and other tumors. Resistance to immunotherapy in GBM patients may be caused by acquisition of immunosuppressive ability by tumor cells and an altered tumor microenvironment. Although novel strategies using an immune...
Autores principales: | Miyazaki, Tsubasa, Ishikawa, Eiichi, Sugii, Narushi, Matsuda, Masahide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409093/ https://www.ncbi.nlm.nih.gov/pubmed/32707672 http://dx.doi.org/10.3390/cancers12071960 |
Ejemplares similares
-
RT-4 Treatment outcome of proton beam therapy for glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2021) -
IM-6 HVJ-E containing PD-L1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
por: Sugii, Narushi, et al.
Publicado: (2021) -
RT-02 POTENTIAL OF PROTON BEAM THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
por: Matsuda, Masahide, et al.
Publicado: (2019) -
P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients
por: Yamada, Erika, et al.
Publicado: (2023) -
High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis
por: Matsuda, Masahide, et al.
Publicado: (2023)